Vivos Therapeutics Inc expected to post a loss of 61 cents a share - Earnings Preview

Vivos Therapeutics

08/11/2024 22:22

* Vivos Therapeutics Inc  VVOS.OQ   VVOS.O  is expected
to show a
rise in quarterly revenue when it reports  results on November
12 (estimated) for the period ending September 30 2024
    * The Littleton Colorado-based  company is expected to
report a
23.0% increase in revenue to $4.061 million from $3.3 million a
year ago, according to the estimate from one analyst, based on
LSEG data.
    * ​LSEG's mean analyst estimate for Vivos Therapeutics Inc
is for
a loss of 61 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Vivos
Therapeutics Inc is $7.43​, above​ its last closing price
of $2.84. ​​​

This summary was machine generated November 8 at 22:22 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)